John Nakayama, MD, a luminary in gynecologic oncology and translational research, has been named Vice Chair of the NRG Ancillary Projects Committee, succeeding Dr. Bridget Koontz who ascended to Chair. Dr. Nakayama directs Translational Research within Allegheny Health Network’s Division of Gynecologic Oncology and serves as an associate professor at Drexel University College of Medicine. His pioneering efforts center on precision oncology, notably through the development and validation of circulating tumor DNA (ctDNA) biomarkers. His work involves rigorous analysis of homologous recombination deficiency and molecular residual disease, which holds significant sway in predicting patient responses to platinum-based chemotherapies. Dr. Nakayama’s leadership in integrating artificial intelligence and machine learning methodologies into gynecologic cancer research exemplifies the cutting edge of oncology. His models enhance predictions for ovarian cancer recurrence, anticipate chemotherapy toxicity profiles, and innovate with synthetic data applications — an intersection that promises personalized therapeutic adjustments.

In the realm of surgical oncology, Dr. Ibrahim Nassour, MD, MSCS, FACS, has advanced to Vice Chair of the NRG Surgical Oncology Committee. Dr. Nassour’s leadership at the University of Florida encompasses direction of robotic surgical programs and regional cancer therapies, facilitating translational research that improves gastric cancer patient navigation and care coordination. His involvement as a pivotal investigator in national clinical trials funded through the NCI’s network highlights his commitment to expanding evidence-based surgical interventions. Critical to his role is the facilitation of robotic surgery innovations and the integration of data-driven patient outcomes to elevate surgical oncology standards.

Turning to sarcoma, a historically challenging and heterogeneous group of malignancies, Dr. Scott Okuno, MD, assumes Vice Chair of the NRG Sarcoma Subcommittee. Dr. Okuno balances his responsibilities as Chief Medical Officer for the Sarcoma Alliance for Research through Collaboration with his academic leadership at Mayo Clinic. His research portfolio targets the development of novel, targeted therapies specially tailored to sarcoma subtypes, including leiomyosarcoma. Dr. Okuno’s involvement with multi-institutional clinical trials, such as ARST1321 investigating the role of pazopanib in combination with chemoradiation, addresses critical unmet needs in sarcoma treatment by exploring histology-specific biological pathways and therapeutic responses. This work marks a considerable step forward in precision oncology for sarcoma patients whose options have historically been limited.

Enhancing investigator development, Dr. Angeles Alvarez Secord, MD, MHSc, now leads as Chair of the NRG Investigator & Career Development Committee. Based at Duke University, Dr. Secord has fostered a broad consortium focused on the molecularly informed treatment of endometrial cancer, reflecting her dedication to translating molecular insights into practical therapeutic advances. Her leadership in mentoring emerging clinical investigators and her prior presidency of the Society of Gynecologic Oncology highlight her influential role in shaping the next generation of oncologic researchers. Dr. Secord’s work exemplifies the critical nexus of clinical trials, career development, and molecular oncology, driving forward new paradigms in cancer treatment and research mentorship.

Focusing on patient-reported outcomes and equitable health care, Dr. Samantha Tam, MD, MPH, FRCSC, was appointed Vice Chair of the NRG Patient-Centered Outcomes Research Committee. Leading research efforts at Henry Ford Health System, Dr. Tam has established comprehensive patient-reported outcome measures (PROMs) programs embedded within routine oncology practice. Her investigations into the implementation fidelity, equity implications, and clinical relevance of PROMs ensure that patient experiences and quality-of-life metrics become integral to cancer care protocols. At NRG, her role includes co-chairing PRO initiatives for head and neck cancer trials and spearheading cost-effectiveness analyses, bolstering the precision and patient orientation of research efforts.

In the domain of medical oncology, Dr. Christina Wu, MD, has been named Vice Chair of the NRG Medical Oncology Committee. Affiliated with Mayo Clinic Arizona, Dr. Wu’s translational research dissects the molecular and immunologic underpinnings of gastrointestinal cancers, with a particular emphasis on KRAS mutations and mismatch repair-deficient colorectal carcinomas. Her expertise encompasses early-phase clinical trials driven by biomarker stratification and innovative approaches utilizing artificial intelligence and liquid biopsy for risk assessment and recurrence prediction. Supported by prominent funding bodies, Dr. Wu’s work stands at the forefront of integrating cutting-edge molecular diagnostics into clinical protocols, with the goal of refining patient-specific treatment regimens and improving clinical outcomes.

NRG Oncology’s recent leadership transitions thus reflect a deliberate strategy to harness specialized expertise across diverse oncologic disciplines, fostering a collaborative environment where molecular insights, technological advancements, and patient-centered approaches coalesce. This dynamic leadership cadre is poised to influence the trajectory of clinical trial design, biomarker discovery, and translational research, ultimately accelerating the integration of personalized medicine into routine oncology care.

These appointments are not merely administrative changes; rather, they represent a profound investment in scientific innovation and rigorous clinical inquiry. The new leaders bring a spectrum of methodological sophistication, from molecular biology and bioinformatics to health services research and surgical innovation. This multifaceted expertise is critical in addressing the complex, multifactorial nature of cancer and its treatment, ensuring that NRG Oncology remains at the vanguard of research that directly improves patient survival, quality of life, and therapeutic precision.

NRG Oncology, continuing its legacy of integrating formerly independent research groups, maintains a robust infrastructure of over 1,300 research sites, predominantly in North America, enabling extensive clinical trial enrollment and high-quality data acquisition. These leadership enhancements will amplify the group’s capacity to execute landmark clinical trials that influence standard oncologic practice and policy.

The emphasis on novel biomarker development, AI-driven predictive modeling, and patient-reported outcome integration underscores a pivotal shift in cancer research—eschewing one-size-fits-all paradigms in favor of deeply personalized, data-rich strategies that are responsive to individual patient biology and experience. This leadership renewal within NRG Oncology embodies this transformative ethos, promising substantial advances in the fight against cancer.

For detailed information and updates on ongoing leadership and committee openings, stakeholders and prospective participants are encouraged to consult NRG Oncology’s official website which provides comprehensive listings and application timelines.

Subject of Research:
Cutting-edge leadership roles in translational oncology, surgical oncology, sarcoma research, investigator development, patient-centered outcomes, and molecular medical oncology within a leading cancer clinical trials network.

Article Title:
NRG Oncology Announces Strategic Leadership Realignment to Propel Cancer Research Innovation

News Publication Date:
Not explicitly stated (content references appointments effective 2026 and awards in 2025, indicating a future-dated publication)

Web References:
https://www.nrgoncology.org/Current-Openings
http://www.nrgoncology.org

Keywords:
NRG Oncology, cancer research, clinical trials, translational research, precision oncology, circulating tumor DNA, gynecologic oncology, surgical oncology, sarcoma, investigator development, patient-reported outcomes, medical oncology, artificial intelligence, biomarker-driven trials

In a pioneering effort to harness cutting-edge artificial intelligence (AI) technologies for clinical benefit, Sylvester researchers are co-leading the PRISM Trial—a $16 million multi-center study funded by the Patient-Centered Outcomes Research Institute (PCORI). This large-scale pragmatic randomized trial endeavors to assess whether AI can augment radiologists’ accuracy in interpreting mammograms. By evaluating hundreds of thousands of scans across diverse geographic settings, including California, Florida, Massachusetts, Washington, and Wisconsin, this research aims to redefine breast cancer screening protocols and reduce diagnostic errors. Such integration of AI holds promise not only for earlier detection but also for diminishing the burdens of false positives and negatives that compromise patient outcomes.

On the neurological oncology front, Sylvester’s investigations into glioblastoma—the most aggressive and lethal form of brain cancer—have yielded transformative insights into tumor cell behavior. Contrary to prior assumptions emphasizing isolated cellular aggression, this research uncovers that glioblastoma cells exhibit a spectrum of adhesive behaviors. Cells that remain “clustered” tend to be less malignant, whereas those that disengage from their neighboring cohorts demonstrate heightened invasiveness and lethality. Extending these observations to breast cancer tissues suggests a broader oncological paradigm wherein cellular cohesion influences metastatic potential. This discovery, published in the esteemed journal Cancer Cell, paves the way for novel therapeutic strategies that could target tumor cell adhesion mechanisms to retard cancer progression.

Meanwhile, the landscape of hematologic malignancies continuously evolves, underscored by Sylvester’s critical evaluation of AI tools such as ChatGPT in patient education and clinical decision support. Researchers critically appraised ChatGPT’s responses to pertinent blood cancer queries, revealing a dichotomy: while the AI excelled in addressing general oncology questions, it exhibited deficiencies when discussing cutting-edge therapies and nuanced treatment modalities. This underscores the imperative for patients and clinicians alike to approach AI-generated medical information with prudent skepticism. As advanced therapies rapidly emerge in hematology, expert oversight remains indispensable to ensure patient safety and optimal care.

In parallel endeavors, Sylvester scientists have meticulously charted the timeline of genomic insults culminating in multiple myeloma, the second most prevalent blood cancer. Leveraging sophisticated genome sequencing and molecular profiling techniques, this study delineates a chronology of DNA damage events that precede symptomatic disease. By unlocking the intricacies of these genetic trajectories, researchers aim to classify multiple myeloma into biologically and clinically relevant subtypes. Such refined stratification holds profound implications for the advancement of precision oncology, enabling tailored treatment regimens that optimize efficacy and minimize toxicity.

Expanding the molecular understanding of lymphoma, a Sylvester-led team secured a substantial $2.4 million grant from the National Cancer Institute to explore the role of the cyclin G-associated kinase (GAK) protein in diffuse large B-cell lymphoma (DLBCL). This investigation probes uncharted facets of lymphoma biology, particularly how GAK modulates cellular processes driving oncogenesis. Unveiling these mechanisms may herald new drug targets, offering therapeutic avenues beyond conventional chemotherapeutic strategies. This initiative exemplifies the relentless pursuit of innovation in combating hematologic cancers.

Complementing these advances in cancer biology and therapeutics, Sylvester Cancer Center’s clinical research affirms the transformative potential of remote perioperative monitoring (RPM) in enhancing postoperative outcomes for cancer patients. In a controlled trial involving approximately 300 surgery recipients, RPM facilitated real-time patient assessment during the critical two-week post-surgical window, significantly reducing complications and accelerating recovery. By integrating wearable sensors and telehealth platforms, RPM empowers clinicians to swiftly identify and address adverse events, thereby elevating standards of care and patient satisfaction.

Leadership at Sylvester continues to influence the broader oncology community, exemplified by Dr. Mikkael Sekeres’s election to the executive committee of the American Society of Hematology (ASH). This appointment reflects Sylvester’s commitment to shaping hematology research and clinical practice at national and international levels, further cementing the center’s role as a vanguard institution in blood cancer management.

These collective efforts underscore a multidisciplinary approach that synergizes environmental health, artificial intelligence, molecular biology, and patient-centered care. As cancer remains a formidable global health challenge, innovations emanating from Sylvester Comprehensive Cancer Center invigorate hope for more effective interventions and improved survival rates across diverse malignancies.

The integration of environmental data with oncological outcomes exemplifies the expanding paradigm of cancer research—recognizing that genetics alone cannot account for disparities in cancer aggressiveness. Likewise, the incorporation of AI into diagnostic workflows anticipates a future where augmented intelligence bolsters human expertise rather than supplants it. Novel findings regarding tumor cell adhesion dynamics invite a reevaluation of metastasis models, suggesting therapeutic targeting of physical cell-cell interactions.

Moreover, scrutinizing AI’s performance in conveying complex medical information serves as a cautionary tale, emphasizing that technology is a complement, not a replacement, for professional medical judgment. Genetic mapping of disease progression in multiple myeloma and molecular characterization of lymphoma biology both herald precision medicine’s promise, fostering treatments attuned to individual patient profiles.

Finally, the successful implementation of remote-monitoring technologies during vulnerable recovery periods offers a template for leveraging digital health to enhance surgical outcomes and patient quality of life. These advancements collectively chart an optimistic trajectory for the future of oncology research and care, grounded in rigorous science and multidisciplinary collaboration.

Subject of Research: Cancer biology, environmental health impacts, AI in diagnostic imaging, hematologic malignancies, surgical recovery monitoring
Article Title: October 2025 Cancer Research Highlights from Sylvester Comprehensive Cancer Center: From Toxic Sites to AI and Beyond
News Publication Date: October 2025
Web References:
– Sylvester Comprehensive Cancer Center: https://umiamihealth.org/en/sylvester-comprehensive-cancer-center
– PRISM Trial on AI in Mammography: https://news.med.miami.edu/studying-artificial-intelligence-in-breast-cancer-screening/
– Glioblastoma Cell Adhesion Study in Cancer Cell: https://www.cell.com/cancer-cell/fulltext/S1535-6108(25)00366-6
– ChatGPT Blood Cancer Accuracy Study: https://www.tandfonline.com/doi/full/10.1080/20565623.2025.2546259
– Multiple Myeloma DNA Damage Timeline in Nature Genetics: https://www.nature.com/articles/s41588-025-02292-1
– Remote Perioperative Monitoring Study in npj Digital Medicine: https://www.nature.com/articles/s41746-025-01961-z
– American Society of Hematology: https://www.hematology.org/
References: Links as indicated above
Image Credits: Photo by Sylvester Comprehensive Cancer Center
Keywords: Cancer research, Translational research, Blood cancer, Brain cancer, Breast cancer, Leukemia, Lymphoma, Multiple myeloma

The new funding will facilitate sixteen groundbreaking patient-centered CER studies, each crafted to address unique health challenges that face a cross-section of the population. These projects signal a commitment to understanding not only the efficacy of various treatment options but also their impacts on the quality of life and long-term health trajectories of patients. Such an approach underscores the importance of research that prioritizes patient perspectives, an element often overlooked in conventional clinical trials, which may focus predominantly on clinical endpoints.

One highlight of this funding round is the focus on long-term follow-up studies pertaining to patient outcomes. Eight of these studies will assess the enduring effects of previously examined treatments, interventions, and programs. This is critical, as the implications of a health intervention may evolve over time, necessitating ongoing evaluation to fully understand potential benefits and risks associated with specific treatment pathways. By taking a long-view approach, PCORI seeks to elucidate vital information that directly affects patient well-being and inform health care decision-making processes.

In exploring the specific areas of research funded, the studies encompass a range of pertinent topics. From examining durations of antibiotic treatment for pediatric hospitalizations to investigating treatment strategies for neurodevelopmental differences in young children, the breadth of these studies reflects a comprehensive understanding of the diverse health care challenges patients encounter daily. Particularly notable is the attention to interventions for pediatric anxiety, which underscores an increasing recognition of mental health as an integral component of an individual’s overall health profile.

Additionally, the funded studies will investigate the use of emerging technologies in health care. For instance, one study will analyze the effectiveness of mammography assisted by artificial intelligence, exploring how technological advancements can influence diagnostic accuracy and ultimately, patient outcomes. This fusion of technology with traditional health care practices holds promise for revolutionizing how conditions are diagnosed and treated, potentially leading to earlier interventions and improved survival rates among patients.

Moreover, the research endeavors also delve into specialized fields concerning rare diseases, including conditions like spina bifida and amyotrophic lateral sclerosis (ALS). These populations often experience significant barriers in obtaining adequate care and treatment options, making studies focusing on their unique needs particularly vital. By funding research in this area, PCORI aims to foster a deeper understanding of the challenges faced by these patients and to generate actionable insights that can enhance their health care experience.

As part of its overarching strategy to advance patient-centered research, PCORI acknowledges the often-protracted timeline between generating research findings and their translation into clinical practice. To tackle this issue, the organization has initiated the Health Systems Implementation Initiative (HSII), which focuses on accelerating the integration of research results into everyday clinical settings. By awarding 19 distinct grants under this initiative, PCORI aims to address persistent barriers and promote more immediate application of research insights to improve patient care.

Among the HSII-funded projects are efforts aimed at enhancing the management of hypertension, electronic monitoring of patient-reported outcomes during cancer treatments, and optimizing outpatient antibiotic prescribing. Such measures not only have the potential to improve individual patient outcomes but also to address public health issues, such as antibiotic resistance, by promoting judicious use of antibiotics among pediatric patients with acute respiratory infections.

Importantly, PCORI’s strategic direction includes allocating resources to perfect research methodologies and enhance community engagement in scientific research. By supporting studies that focus on research methods and patient engagement, PCORI aims to deepen the trust between researchers and the communities they serve, ensuring that research is not merely conducted on patients but rather conducted with their active participation. This paradigm shift toward collaborative research can yield findings that are more relevant and impactful for communities, addressing the specific needs and preferences of patients.

As the health care landscape continues to evolve, organizations like PCORI play a crucial role in steering research towards a more patient-centric model. The embrace of CER not only acknowledges the complex realities that patients face but also strives to arm them with the information necessary to navigate their health care journeys effectively. With funding now flowing into pivotal research studies and innovative initiatives, there is renewed hope that the troubling discrepancies between research evidence and clinical practice can be bridged, paving the way for enhanced health outcomes for all.

As PCORI rolls out these ambitious funding plans, it is clear that the future of clinical research is leaning towards more inclusive, transparent, and patient-informed practices. This collective movement signals a vibrant shift in how health research can and should be conducted, ultimately striving toward a health care system that upholds the voice and needs of the patient at its core.

Subject of Research: Patient-Centered Comparative Clinical Effectiveness Research
Article Title: Empowering Patients Through New Funding for Comparative Clinical Effectiveness Research
News Publication Date: April 8, 2025
Web References: PCORI
References: None
Image Credits: Patient-Centered Outcomes Research Institute

Keywords: Clinical Research, Patient-Centered Outcomes, Comparative Effectiveness Research, Health Decisions, Long-Term Health Outcomes, Healthcare Implementation, Patient Engagement